An expensive new drug for HIV pre-exposure prophylaxis (PrEP) is unlikely to confer any discernible health benefit over generic alternatives and may undermine efforts to expand access to HIV prevention for the nation's most vulnerable populations, a new study led by researchers at the Yale School of Public Health (YSPH) and Massachusetts General Hospital (MGH) finds.
Published: Monday, April 6, 2020
